
|Videos|May 18, 2017
Long-Term Strategies in Advanced HCC
Long-Term Strategies in Advanced HCC
Advertisement
May 2016
- A 70-year old male with metastatic HCC involving the lung and bone confirmed by biopsy, experiencing mild bone pain
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 1 HTN and grade 1 hand-foot skin reaction, which was managed effectively
April 2017
- Documented radiographic progression
- Therapy with regorafenib at 160mg was initiated
- Patient experienced grade 1 HTN, grade 2 hand-foot skin reaction
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5
































